论文部分内容阅读
目的通过体外细胞培养研究沙利度胺(Tha)作用于肝细胞癌(HCC)细胞株SMMC7721,探讨Tha抗HCC的作用机制。方法根据参考文献[1]确定各组药物的最适作用浓度后,通过不同浓度Tha分别与HCC细胞SMMC7721体外培养,以MTT法检测细胞增殖活性,免疫组化法测血管内皮生长因子(VEGF)蛋白表达变化,流式细胞仪检测细胞凋亡率。结果不同浓度、不同时间Tha组细胞抑制率比较,差异有统计学意义(P<0.01)。不同浓度Tha组作用于SMMC7721细胞48h后,VEGF蛋白表达和细胞凋亡率随浓度增高而增加(P<0.05)。结论Tha是有效的辅助抗肝癌药物。
Objective To investigate the effect of thalidomide (Tha) on hepatocellular carcinoma (HCC) cell line SMMC7721 in vitro and to explore the mechanism of Tha anti-HCC. Methods According to references [1] to determine the optimal concentration of each group of drugs, respectively, with different concentrations of Tha and HCC cells SMMC7721 cultured in vitro, MTT assay cell proliferation activity, immunohistochemical method to detect vascular endothelial growth factor (VEGF) Protein expression changes, flow cytometry detection of apoptosis rate. Results There were significant differences in inhibition rate of Tha between different concentrations and time (P <0.01). After treated with different concentrations of Tha for 48h, the expression of VEGF and the rate of apoptosis increased with increasing concentrations of Tha in SMMC7721 cells (P <0.05). Conclusion Tha is an effective adjuvant anti-hepatoma drug.